Proteomic analysis of human prostate cancer†

Mamoun Ahram(National Institutes of Health), Carolyn J.M. Best(National Institutes of Health), Michael J. Flaig(National Institutes of Health), John W. Gillespie(National Institutes of Health), Isabel M. Leiva(National Institutes of Health), Rodrigo Chuaqui(National Institutes of Health), Ge Zhou(The University of Texas Southwestern Medical Center), Hungjun Shu(The University of Texas Southwestern Medical Center), Paul H. Duray(National Institutes of Health), W. Marston Linehan(National Institutes of Health), Mark Raffeld(National Institutes of Health), David K. Ornstein(University of North Carolina at Chapel Hill), Yingming Zhao(The University of Texas Southwestern Medical Center), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Michael R. Emmert‐Buck(National Institutes of Health)
Molecular Carcinogenesis
January 1, 2002
Cited by 140

Abstract

Proteomics is a promising approach in the identification of proteins and biochemical pathways involved in tumorigenesis. In an effort to discover such proteins and pathways that are deregulated in prostate tumorigenesis, cellular proteomes of matched normal prostate epithelial cells and high-grade prostate cancer cells were analyzed by tissue microdissection, two-dimensional electrophoresis, and mass spectrometry. Forty protein alterations were detected in the tumors; however, the majority of these changes were not shared among the 12 neoplasms. In contrast, parallel cDNA microarray analysis identified a number of common gene expression changes. The marked heterogeneity of the observed protein alterations may have significance with regard to tumor biology and research strategies for molecular profiling analyses of human prostate cancer.


Related Papers

No related papers found

Powered by citation graph analysis